Azithromycin

Urethritis, Chancroid, Tonsillitis + 34 more

Treatment

32 FDA approvals

20 Active Studies for Azithromycin

What is Azithromycin

Azithromycin

The Generic name of this drug

Treatment Summary

Azithromycin is an antibiotic used to treat a wide range of bacterial infections, including respiratory, enteric, and genitourinary infections. It belongs to the macrolide family and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring. This helps prevent its metabolism and allows it to be used instead of other macrolides in some cases. In March 2020, a study funded by the French government explored the use of a combination of azithromycin and hydroxychloroquine to treat COVID

Zithromax

is the brand name

Azithromycin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zithromax

Azithromycin

1994

541

Approved as Treatment by the FDA

Azithromycin, otherwise called Zithromax, is approved by the FDA for 32 uses including Bacterial Sinusitis and Sinusitis .

Bacterial Sinusitis

Sinusitis

Haemophilus Influenzae Infections

Genus Chlamydia

patients appropriate for oral therapy

Tonsillitis bacterial

genital ulcers caused by haemophilus ducreyi infection

Acute Otitis Media (AOM)

Streptococcus pyogenes

Streptococcal Pharyngitis

Tonsillitis streptococcal

unable to prescribe first line therapy for streptococcus pyogenes tonsillitis

Tonsillitis

Haemophilus ducreyi infection

Moraxella Catarrhalis Infection

Community Acquired Pneumonia (CAP)

Moraxella catarrhalis

ABDIC protocol

Adults

Streptococcus Pneumoniae Infections

Adult Patients

Genital Ulcer Disease (GUD)

Communicable Diseases

Staphylococcus (S.) Aureus Infection

Pneumococcal Infections

Pneumonia, Mycoplasma

Tonsillitis

Pediatric Patients

Otitis

Sore Throat

Streptococcus pyogenes

Streptococcus Agalactiae Infection

Effectiveness

How Azithromycin Affects Patients

Macrolides are a type of medicine used to treat bacterial infections. They work by stopping bacteria from making proteins, which are needed for them to grow and spread. Azithromycin has additional benefits, as it can also help reduce inflammation related to certain respiratory illnesses.

How Azithromycin works in the body

Azithromycin is an antibiotic that works by stopping bacteria from making proteins. It does this by preventing the assembly of the bacterial ribosome's 50S subunit. This stops the bacteria from replicating, which in turn helps control various bacterial infections. Azithromycin is especially effective because it is able to stay stable in low pH environments and can therefore stay in your body for longer, allowing it to maintain higher concentrations in your tissues than other antibiotics like erythromycin.

When to interrupt dosage

The prescribed amount of Azithromycin is contingent upon the identified issue, for example Streptococcus Agalactiae Infection, Chlamydia trachomatis and Genus Chlamydia. The dosage likewise fluctuates as per the technique of delivery outlined in the table below.

Condition

Dosage

Administration

Streptococcus Agalactiae Infection

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Urethritis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Chancroid

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Conjunctivitis, Bacterial

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Communicable Diseases

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Otitis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Tonsillitis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Chlamydia trachomatis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Genus Chlamydia

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Genital Ulcer Disease (GUD)

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Haemophilus ducreyi infection

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Streptococcus pyogenes

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Moraxella catarrhalis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Uterine Cervicitis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Sinusitis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Adult Patients

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Tonsillitis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Bacterial conjunctivitis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Pneumonia, Mycoplasma

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Communicable Diseases

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Warnings

Azithromycin Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Azithromycin may interact with Pulse Frequency

Jaundice, Obstructive

Do Not Combine

prior azithromycin use

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Azithromycin may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Azithromycin may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Azithromycin may interact with Pulse Frequency

There are 20 known major drug interactions with Azithromycin.

Common Azithromycin Drug Interactions

Drug Name

Risk Level

Description

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Anagrelide.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Artemether.

Asenapine

Major

The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Asenapine.

Astemizole

Major

The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Astemizole.

Azithromycin Toxicity & Overdose Risk

Azithromycin has an oral LD50 (lowest toxic dose) of greater than 2000mk/kg in rats. Possible major side effects include abnormal heart rhythms and hearing loss. There is also a chance of developing resistance to the drug. Liver toxicity has been reported in rare cases, and caution should be taken when giving the drug to those with decreased liver function. Azithromycin has not been studied in pregnant women, but animal studies have not shown harmful effects on the fetus. It is unknown if the drug is passed through breast milk, so caution should be used when giving the drug to nursing mothers. Animal studies have not found

Azithromycin Novel Uses: Which Conditions Have a Clinical Trial Featuring Azithromycin?

At present, 9 active clinical trials are researching the potential of Azithromycin to treat Moraxella Catarrhalis Infection, Staphylococcus (S.) Aureus Infection and Communicable Diseases.

Condition

Clinical Trials

Trial Phases

Sinusitis

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Staphylococcus (S.) Aureus Infection

2 Actively Recruiting

Phase 4, Phase 1

Conjunctivitis, Bacterial

0 Actively Recruiting

Streptococcus pyogenes

0 Actively Recruiting

Moraxella catarrhalis

0 Actively Recruiting

Streptococcus Agalactiae Infection

0 Actively Recruiting

Haemophilus Influenzae Infections

0 Actively Recruiting

Uterine Cervicitis

0 Actively Recruiting

Genital Ulcer Disease (GUD)

0 Actively Recruiting

unable to prescribe first line therapy for streptococcus pyogenes tonsillitis

0 Actively Recruiting

Bacterial conjunctivitis

0 Actively Recruiting

Streptococcus pyogenes

0 Actively Recruiting

Diarrhea

0 Actively Recruiting

Tonsillitis

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Pneumococcal Infections

0 Actively Recruiting

Pediatric Patients

0 Actively Recruiting

Adult Patients

0 Actively Recruiting

Chancroid

0 Actively Recruiting

Patient Q&A Section about azithromycin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is azithromycin a strong antibiotic?

"Azithromycin is a popular antibiotic medication that treats a variety of health conditions by stopping the growth of certain types of bacteria. It is easy to use, generally affordable, and highly effective."

Answered by AI

Why azithromycin is given for 3 days?

"It was concluded that a 3-day regiment of azithromycin prescribed as tablets is just as effective as a 10-day regiment of co-amoxiclav in the treatment of acute lower respiratory tract infections."

Answered by AI

What are the side effects of azithromycin?

"If you're feeling nauseous, stick to simple meals and avoid rich or spicy cuisine while taking this medication. If you experience diarrhea, be sure to drink lots of fluids such as water or juice to prevent dehydration. If you vomit, ... If you lose your appetite, ... If you have a headache, ... If you're feeling dizzy or tired, ... If your sense of taste changes, ..."

Answered by AI

What is a azithromycin used for?

"Azithromycin is used to treat certain bacterial infections, such as bronchitis; pneumonia; sexually transmitted diseases (STD); and infections of the ears, lungs, sinuses, skin, throat, and reproductive organs."

Answered by AI

Clinical Trials for Azithromycin

Image of University of Oklahoma Health Sciences Center in Oklahoma City, United States.

Vision Training for Balance Disorders

65 - 80
All Sexes
Oklahoma City, OK

The investigators propose a 2-week intervention involving adults over 65 years old. Participants will undergo dynamic balance training on an movable platform (stabilometer) with either restricted or full vision. The primary objective is to facilitate sensory re-weighting, hypothesizing that restricted vision training will increase somatosensory input utilization for postural control. Pre- and post-training assessments will measure postural control during gait initiation under a dual-task condition. The investigators hypothesize that the restricted vision group will demonstrate: 1. Improved postural control, indicated by increased center of pressure displacement during gait initiation. 2. Improved ability to utilize somatosensory input during a balance task.

Recruiting
Has No Placebo

University of Oklahoma Health Sciences Center

Yo Shih, PhD

Image of Dartmouth-Hitchcock Medical Center in Lebanon, United States.

LGW16-03 for Nerve Identification

18+
All Sexes
Lebanon, NH

The primary goal of this study is to determine the safety and tolerability of LGW16-03, a novel nerve-labeling fluorophore, in participants undergoing open-field orthopaedic surgery. Secondary goals include: 1) identifying the lowest dose without adverse events that provides peak florescence imaging contrast, and 2) characterizing the pharmacokinetics of LGW16-03. Participants will receive a one-time intravenous infusion of the investigational drug (LGW16-03) prior to their planned surgery. Participants' vitals will be closely monitored and will have blood samples taken at regular intervals. Fluorescence images of their major nerve will be taken during surgery. Participants will have one study follow-up visit approximately 30 days after their surgery.

Phase 1
Waitlist Available

Dartmouth-Hitchcock Medical Center

Image of Grady Memorial Hospital in Atlanta, United States.

Point-of-care Testing for Sexually Transmitted Infections

Any Age
Female
Atlanta, GA

The goal of this clinical trial is to learn if point-of-care tests (POCTs) for sexually transmitted infections (STIs) improve the timely treatment of syphilis, chlamydia, gonorrhea, and trichomonas in pregnant women. It will also learn about the feasibility, acceptability, and cost-effectiveness of implementing POCTs in a large safety-net hospital setting. The main questions it aims to answer are: * Do POCTs reduce delays in STI treatment compared with standard laboratory-based testing? * What barriers, facilitators, and processes affect POCT implementation in prenatal and obstetric care? * What are the costs and cost-effectiveness of POCTs compared with standard testing? Participants will: * Complete a baseline survey and receive either POCTs (fingerstick blood draw or vaginal swab) or standard laboratory STI testing. * If diagnosed with an STI, complete a follow-up survey approximately one month later. * Stakeholders (providers, hospital leadership, and public health officials) will complete interviews to inform implementation strategies.

Waitlist Available
Has No Placebo

Grady Memorial Hospital

Kristin Wall, PhD

Have you considered Azithromycin clinical trials?

We made a collection of clinical trials featuring Azithromycin, we think they might fit your search criteria.
Go to Trials
Image of Centre for Urban Innovation (CUI-109), School of Nutrition, Toronto Metropolitan University in Toronto, Canada.

White Potatoes for Glycemic Responses

18 - 65
All Sexes
Toronto, Canada

The purpose of this study is to evaluate the interaction between white potato consumption and meal timing on glycemic response, subjective appetite, and energy intake in adults. The investigators hypothesize that white potatoes will modulate glycemic response, enhance satiety, and mitigate subsequent meal consumption and overall food intake when compared with meals containing low glycemic carbohydrates. Furthermore, they anticipate that the timing of white potato consumption will yield differential effects, with breakfast consumption exerting a more pronounced impact on satiety and subsequent food intake reduction compared to dinner consumption.

Recruiting
Has No Placebo

Centre for Urban Innovation (CUI-109), School of Nutrition, Toronto Metropolitan University

Image of Cross Cancer Institute in Edmonton, Canada.

Exercise for Peripheral Neuropathy

18+
All Sexes
Edmonton, Canada

CYCLE-CIPN is a proof-of-concept study designed to evaluate whether a prescribed aerobic exercise intervention has the potential to reduce the symptoms and functional impact of CIPN. The small number of participants in the proposed study will allow us to make decisions on the feasibility ("go/no-go") of a future larger-scale trial. The protocol will assess feasibility and acceptability through recruitment, completion, adherence, program satisfaction, and safety. The study will also evaluate CIPN symptoms using both patient-reported and objective outcome measures, as well as fitness and quality of life outcomes. We aim to recruit 30 participants. The Health Research Board of Alberta Cancer Committee has approved this study. Participants will participate in a stationary cycling-based aerobic exercise program biweekly for 12 weeks. Exercise sessions will be supervised and progressive, between 30 and 60 minutes each.

Recruiting
Has No Placebo

Cross Cancer Institute

Margaret L McNeely, PhD

Have you considered Azithromycin clinical trials?

We made a collection of clinical trials featuring Azithromycin, we think they might fit your search criteria.
Go to Trials
Image of Children's Healthcare of Atlanta in Atlanta, United States.

Antibiotic Strategies for Pneumonia in Children

12 - 71
All Sexes
Atlanta, GA

The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are: * To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP) * To identify which patient groups benefit most from the SNAP strategy * To identify factors that shape implementation of each prescribing strategy. Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other. Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.

Recruiting
Has No Placebo

Children's Healthcare of Atlanta (+3 Sites)

Todd Florin, MD, MSCE

Image of USC Voice Center in Arcadia, United States.

Voice Therapy for Age-Related Voice Change

18+
All Sexes
Arcadia, CA

This study compares how well voice therapy works when delivered in-person versus through telehealth for older adults with age-related voice problems. Researchers are testing whether Phonation Resistance Training Exercises (PhoRTE®) can be just as effective when delivered remotely as when done face-to-face, which could make treatment more accessible and affordable for seniors. The two primary hypotheses are: 1. Does voice therapy (called PhoRTE®) work as well through video calls as it does face-to-face? 2. Can online therapy be a more accessible way for older adults to get help for their voice problems? Adults aged 55 or older with voice changes and an applicable diagnosis will be randomly assigned to receive either in-person or telehealth therapy, consisting of four 45-minute sessions. After treatment, researchers will measure improvements through: * Changes in voice function * Patient reports about their voice * Scientific measurements of voice quality * Patient satisfaction with treatment * Impact on quality of life The results will help determine if telehealth can be a good alternative to in-person voice therapy, especially important as telehealth coverage may be changing.

Waitlist Available
Has No Placebo

USC Voice Center (+3 Sites)

Aaron Rothbart, PhD

Have you considered Azithromycin clinical trials?

We made a collection of clinical trials featuring Azithromycin, we think they might fit your search criteria.
Go to Trials